)
Quanterix (QTRX) investor relations material
Quanterix Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Executive summary
Q3 revenue was $34.974M, up 6.3% sequentially but down 13.1% YoY; management characterized the quarter as an initial step toward restoring growth.
Commercial and product strategy changes began supporting Q3 revenue; management expects improvement in Q4 and continued growth in 2027.
LucentAD test volume more than doubled sequentially, spatial consumables neared a record, and Accelerator Lab bookings rose for a second consecutive quarter.
Financial highlights
Q3 revenue was $34.974M versus $40.233M in Q3 2025; adjusted pro forma decline was 8.6%, excluding $2.4M from a terminated program and adding $0.6M of Akoya pre-acquisition revenue to the comparison.
Nine-month revenue rose 10% to $104.3M from $95.0M; product revenue increased 16% to $74.1M, while service and other revenue declined 4% to $28.8M.
Q3 GAAP gross profit was $13.5M; non-GAAP gross profit was $16.6M. GAAP operating loss was $22.5M versus $37.3M, and adjusted operating loss was $18.9M versus $19.8M.
Net loss was $21.6M versus $33.5M; adjusted EBITDA loss was $12.2M versus $11.9M.
Non-GAAP operating expenses were $35.4M, down $2.8M YoY and up $3.7M QoQ, including a one-time compensation timing impact; GAAP operating expenses were $36.0M, down $27.2M YoY.
Outlook and guidance
FY2026 revenue guidance narrowed to $142M–$146M; adjusted gross margin guidance remains 48%–50%.
Year-end 2026 cash guidance is $70M, with no debt; Q3 ended with $80.7M in cash, cash equivalents, marketable securities and restricted cash.
Commercial initiatives are expected to begin lifting revenue in Q4, contribute more materially in 2027 and beyond, and support the unchanged 2027 cash-flow breakeven target.
Q4 growth drivers include Accelerator bookings, instrument placements and consumables; bookings typically convert to billings in four to six months.
Operating losses and negative operating cash flows are expected to continue into 2027; planned spending includes R&D, diagnostics, regulatory submissions and systems enhancements.
- Diagnostics and clinical trials growth, new leadership, and synergy gains drive optimism for 2024.QTRX
Canaccord Genuity's 46th Annual Growth Conference - Q2 2026 revenue up 34% YoY, but guidance cut and breakeven delayed amid execution and market headwinds.QTRX
Q2 2026 - Blood-based diagnostics gain momentum as early detection and monitoring become central to Alzheimer's care.QTRX
Goldman Sachs 45th Annual Global Healthcare Conference - Diagnostics expansion and innovation set to drive growth and cash flow breakeven in H2.QTRX
Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Proxy supplement updates equity plan limits and confirms key votes for the 2026 annual meeting.QTRX
Proxy filing - Q1 2026 revenue up 20% to $36.4M, with improved margins and $85M in cost synergies.QTRX
Q1 2026 - Diagnostics and diversification drive growth as financial discipline and innovation strengthen outlook.QTRX
Leerink Global Healthcare Conference 2026 - Q3 2024 revenue rose 13% to $35.8M; guidance reaffirmed and Emission Inc. acquisition announced.QTRX
Q3 2024 - Record consumables and cost cuts offset revenue decline as Akoya merger and Simoa ONE advance.QTRX
Q1 2025
)
)
)
)
)
)
)
)